Cargando…

Understanding Inflammasomes and PD-1/PD-L1 Crosstalk to Improve Cancer Treatment Efficiency

SIMPLE SUMMARY: Immune checkpoints and inflammasomes have been shown to regulate cancer progression and response to treatments. This review summarizes the recent findings on the crosstalk between the immune checkpoint PD-1 and inflammasomes and the promising association of treatments that might be e...

Descripción completa

Detalles Bibliográficos
Autores principales: Perrichet, Anaïs, Ghiringhelli, François, Rébé, Cédric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7761387/
https://www.ncbi.nlm.nih.gov/pubmed/33261061
http://dx.doi.org/10.3390/cancers12123550
_version_ 1783627556938842112
author Perrichet, Anaïs
Ghiringhelli, François
Rébé, Cédric
author_facet Perrichet, Anaïs
Ghiringhelli, François
Rébé, Cédric
author_sort Perrichet, Anaïs
collection PubMed
description SIMPLE SUMMARY: Immune checkpoints and inflammasomes have been shown to regulate cancer progression and response to treatments. This review summarizes the recent findings on the crosstalk between the immune checkpoint PD-1 and inflammasomes and the promising association of treatments that might be efficient for cancer patients. ABSTRACT: Inflammasomes and immune checkpoints have been shown to participate in carcinogenesis, cancer growth and response to treatment. Thus, targeting cytokines resulting from inflammasome activation, such as interleukin (IL)-1β, has emerged as a new tool in the therapeutic arsenal. Moreover, the use of checkpoint inhibitors such as anti-PD-1 or anti-PD-L1 has revolutionized the treatment of some cancer patients. However, inflammasome activation and consecutive cytokine release only occurs in some chemotherapeutic treatments and immune checkpoint inhibitors only work for a restricted number of patients, thus limiting the use of therapies targeting these pathways. Expanding knowledge about the inefficiency of these therapies recently brought forward the hypothesis of targeting both pathways. In this review, we provide an overview of the crosstalk between inflammasomes and programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) that might explain how these two pathways are mutually dependent, and perhaps why targeting only one of them leads to inefficiency of cancer treatment in some patients.
format Online
Article
Text
id pubmed-7761387
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-77613872020-12-26 Understanding Inflammasomes and PD-1/PD-L1 Crosstalk to Improve Cancer Treatment Efficiency Perrichet, Anaïs Ghiringhelli, François Rébé, Cédric Cancers (Basel) Review SIMPLE SUMMARY: Immune checkpoints and inflammasomes have been shown to regulate cancer progression and response to treatments. This review summarizes the recent findings on the crosstalk between the immune checkpoint PD-1 and inflammasomes and the promising association of treatments that might be efficient for cancer patients. ABSTRACT: Inflammasomes and immune checkpoints have been shown to participate in carcinogenesis, cancer growth and response to treatment. Thus, targeting cytokines resulting from inflammasome activation, such as interleukin (IL)-1β, has emerged as a new tool in the therapeutic arsenal. Moreover, the use of checkpoint inhibitors such as anti-PD-1 or anti-PD-L1 has revolutionized the treatment of some cancer patients. However, inflammasome activation and consecutive cytokine release only occurs in some chemotherapeutic treatments and immune checkpoint inhibitors only work for a restricted number of patients, thus limiting the use of therapies targeting these pathways. Expanding knowledge about the inefficiency of these therapies recently brought forward the hypothesis of targeting both pathways. In this review, we provide an overview of the crosstalk between inflammasomes and programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) that might explain how these two pathways are mutually dependent, and perhaps why targeting only one of them leads to inefficiency of cancer treatment in some patients. MDPI 2020-11-27 /pmc/articles/PMC7761387/ /pubmed/33261061 http://dx.doi.org/10.3390/cancers12123550 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Perrichet, Anaïs
Ghiringhelli, François
Rébé, Cédric
Understanding Inflammasomes and PD-1/PD-L1 Crosstalk to Improve Cancer Treatment Efficiency
title Understanding Inflammasomes and PD-1/PD-L1 Crosstalk to Improve Cancer Treatment Efficiency
title_full Understanding Inflammasomes and PD-1/PD-L1 Crosstalk to Improve Cancer Treatment Efficiency
title_fullStr Understanding Inflammasomes and PD-1/PD-L1 Crosstalk to Improve Cancer Treatment Efficiency
title_full_unstemmed Understanding Inflammasomes and PD-1/PD-L1 Crosstalk to Improve Cancer Treatment Efficiency
title_short Understanding Inflammasomes and PD-1/PD-L1 Crosstalk to Improve Cancer Treatment Efficiency
title_sort understanding inflammasomes and pd-1/pd-l1 crosstalk to improve cancer treatment efficiency
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7761387/
https://www.ncbi.nlm.nih.gov/pubmed/33261061
http://dx.doi.org/10.3390/cancers12123550
work_keys_str_mv AT perrichetanais understandinginflammasomesandpd1pdl1crosstalktoimprovecancertreatmentefficiency
AT ghiringhellifrancois understandinginflammasomesandpd1pdl1crosstalktoimprovecancertreatmentefficiency
AT rebecedric understandinginflammasomesandpd1pdl1crosstalktoimprovecancertreatmentefficiency